576 related articles for article (PubMed ID: 28724663)
41. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
42. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Stutvoet TS; Kol A; de Vries EG; de Bruyn M; Fehrmann RS; Terwisscha van Scheltinga AG; de Jong S
J Pathol; 2019 Sep; 249(1):52-64. PubMed ID: 30972766
[TBL] [Abstract][Full Text] [Related]
43. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Nowicki TS; Akiyama R; Huang RR; Shintaku IP; Wang X; Tumeh PC; Singh A; Chmielowski B; Denny C; Federman N; Ribas A
Cancer Immunol Res; 2017 Feb; 5(2):118-126. PubMed ID: 28039162
[TBL] [Abstract][Full Text] [Related]
44. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
45. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
46. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
47. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Lai X; Friedman A
BMC Syst Biol; 2017 Jul; 11(1):70. PubMed ID: 28724377
[TBL] [Abstract][Full Text] [Related]
49. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J; Vredevoogd DW; Krijgsman O; Ligtenberg MA; Blankenstein S; de Bruijn B; Frederick DT; Kenski JCN; Parren M; Brüggemann M; Madu MF; Rozeman EA; Song JY; Horlings HM; Blank CU; van Akkooi ACJ; Flaherty KT; Boland GM; Peeper DS
Nat Commun; 2020 Aug; 11(1):3946. PubMed ID: 32770055
[TBL] [Abstract][Full Text] [Related]
50. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
51. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
[No Abstract] [Full Text] [Related]
52.
Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
[No Abstract] [Full Text] [Related]
53. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract][Full Text] [Related]
54. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
55. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
Whipple CA; Boni A; Fisher JL; Hampton TH; Tsongalis GJ; Mellinger DL; Yan S; Tafe LJ; Brinckerhoff CE; Turk MJ; Mullins DW; Fadul CE; Ernstoff MS
Melanoma Res; 2016 Jun; 26(3):223-35. PubMed ID: 26974965
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
57. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
58. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C; Peng W; Xu C; Lou Y; Zhang M; Wargo JA; Chen JQ; Li HS; Watowich SS; Yang Y; Tompers Frederick D; Cooper ZA; Mbofung RM; Whittington M; Flaherty KT; Woodman SE; Davies MA; Radvanyi LG; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2013 Jan; 19(2):393-403. PubMed ID: 23204132
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
60. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]